Full Press Release Details
Reports Second Quarter 2016 Results
net business wins of $502 million, a net book to bill of 1.22.
of business grows 8.6% year on year to surpass $4 billion for the
revenue increases 5.7% to $411 million in the quarter.
from operations increases 14.5% to $78 million, before non-recurring
per share increases 20% to $1.14, before non-recurring charges.
share repurchase programme of up to c$400 million.
guidance for 2016 re-affirmed in the range of $4.60 - $4.80 and
revenue guidance revised to be in the range of $1,665 - $1,680 million.
DUBLIN--(BUSINESS WIRE)--July 26, 2016--ICON plc (NASDAQ:ICLR),
a global provider of drug development solutions and services to the
pharmaceutical, biotechnology and medical device industries, today
reported its financial results for the second quarter ended June 30,
Gross business wins in the second quarter were a record $622 million and
cancellations in the quarter were $120 million, resulting in record net
business wins of $502 million, a net book to bill of 1.22.
In the second quarter net revenue grew 5.7% year on year to $410.6
million from $388.7 million in the same quarter last year.
Income from operations, before non-recurring charges in the quarter,
increased by 14.5% to $78.0 million or 19.0% of revenue, compared to
$68.1 million or 17.5% for the same quarter last year.
Net income before non-recurring charges in the quarter increased by
10.4% to $64.7 million or $1.14 per share on a diluted basis, compared
with $58.6 million or $0.95 per share for the same quarter last year.
Revenue in the first half of 2016 increased by 4.4% to $811.2 million
from $776.9 million in 2015.
Income from operations in the first half of 2016, before non-recurring
charges, increased by 14.3% to $154.0 million or 19.0% of revenue
compared with $134.8 million or 17.4% of revenue in the previous year.
Net income in the first half of 2016, before non-recurring charges,
increased by 11.5% to $127.6 million compared with $114.5 million last
year. Year to date earnings increased by 22% to $2.26 per share on a
diluted basis compared to $1.85 per diluted share last year.
Guidance for the full year 2016 has been updated with earnings
reaffirmed in the range of $4.60 - $4.80 and revenue revised to a range
of $1,665 - $1,680 million.
Day's sales outstanding, comprising accounts receivable and unbilled
revenue less payments on account, were 46 days at June 30, 2016,
compared with 47 days at the end of March 31, 2016 and 45 days at the
Cash generated from operating activities for the quarter was $17.9
million. Capital expenditure for the quarter was $12.2 million. As a
result, at June 30, 2016, the company had net debt of $97 million,
compared to net debt of $100 million at March 31, 2016 and net cash of
$132 million at end of June 2015.
At the company's recent AGM we received shareholder approval to
repurchase shares. We will implement a share repurchase programme of up
to c$400m to be completed over the next 18-24 months.
During the quarter the company recorded a charge of $4.1 million in
relation to restructuring costs. US GAAP income from operations after
these items amounted to $73.9 million or 18% of revenue. US GAAP net
income for the quarter was $61.0 million or $1.08 per diluted share.
CEO Ciaran Murray commented "Through a consistent focus on our
strategic plan we achieved a record level of net business awards of $502
million and grew our backlog by almost 9% over last year. We
delivered record revenue of $411 million and grew earnings per share by
20% to $1.14. We are reaffirming our 2016 earnings guidance to be in the
range of $4.60 to $4.80 and revising our revenue guidance to be in the
range of $1,665 - $1,680 million."
In addition to the financial measures prepared in accordance with
generally accepted accounting principles (GAAP), this press release
contains certain non-GAAP financial measures, including non-GAAP
operating and net income and non-GAAP diluted earnings per share. While
non-GAAP financial measures are not superior to or a substitute for the
comparable GAAP measures, ICON believes certain non-GAAP information is
useful to investors for historical comparison purposes.
ICON will hold its second quarter conference call today, July 26, 2016
at 9:00 EDT [14:00 Ireland & UK]. This call and linked slide
presentation can be accessed live from our website at http://investor.iconplc.com.
A recording will also be available on the website for 90 days following
the call. In addition, a calendar of company events, including upcoming
conference presentations, is available on our website, under
"Investors". This calendar will be updated regularly.
This press release contains forward-looking statements. These statements
are based on management's current expectations and information currently
available, including current economic and industry conditions. These
statements are not guarantees of future performance or actual results,
and actual results, developments and business decisions may differ from
those stated in this press release. The forward-looking statements are
subject to future events, risks, uncertainties and other factors that
could cause actual results to differ materially from those projected in
the statements, including, but not limited to, the ability to enter into
new contracts, maintain client relationships, manage the opening of new
offices and offering of new services, the integration of new business
mergers and acquisitions, as well as economic and global market
conditions and other risks and uncertainties detailed from time to time
in SEC reports filed by ICON, all of which are difficult to predict and
some of which are beyond our control. For these reasons, you should not
place undue reliance on these forward-looking statements when making
investment decisions. The word "expected" and variations of such words
and similar expressions are intended to identify forward-looking
statements. Forward-looking statements are only as of the date they are
made and we do not undertake any obligation to update publicly any
forward-looking statement, either as a result of new information, future
events or otherwise. More information about the risks and uncertainties
relating to these forward-looking statements may be found in SEC reports
filed by ICON, including its Form 20-F, F-1, S-8 and F-3, which are
available on the SEC's website at http://www.sec.gov.
ICON plc is a global provider of drug development solutions and services
to the pharmaceutical, biotechnology and medical device industries. The
company specialises in the strategic development, management and